127 related articles for article (PubMed ID: 26568242)
1. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
2. Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR.
Birket SE; Davis JM; Fernandez-Petty CM; Henderson AG; Oden AM; Tang L; Wen H; Hong J; Fu L; Chambers A; Fields A; Zhao G; Tearney GJ; Sorscher EJ; Rowe SM
Am J Respir Crit Care Med; 2020 Nov; 202(9):1271-1282. PubMed ID: 32584141
[No Abstract] [Full Text] [Related]
3. Ivacaftor.
Davis PB; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2012 Apr; 11(5):349-50. PubMed ID: 22543461
[No Abstract] [Full Text] [Related]
4. Correlation between Ivacaftor-induced CFTR Activation in Airway Epithelial Cells and Improved Lung Function: A Proof-of-Concept Study.
Debley JS; Barrow KA; Rich LM; Singh P; McKone EF; Nichols DP
Ann Am Thorac Soc; 2020 Aug; 17(8):1024-1027. PubMed ID: 32421352
[No Abstract] [Full Text] [Related]
5. Highlights of the North American Cystic Fibrosis Conference 2011.
Pabary R; Thursfield R; Davies JC
J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S9-13. PubMed ID: 22688370
[No Abstract] [Full Text] [Related]
6. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis.
Taylor-Cousar JL; Robinson PD; Shteinberg M; Downey DG
Lancet; 2023 Sep; 402(10408):1171-1184. PubMed ID: 37699418
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in developing therapeutics for cystic fibrosis.
Strug LJ; Stephenson AL; Panjwani N; Harris A
Hum Mol Genet; 2018 Aug; 27(R2):R173-R186. PubMed ID: 30060192
[TBL] [Abstract][Full Text] [Related]
8. The ageing of Cystic Fibrosis patients with new modulators: current gaps and challenges.
Felipe Montiel A; Álvarez Fernández A; Traversi L; Polverino E
Expert Rev Respir Med; 2023 Dec; 17(12):1091-1094. PubMed ID: 38347811
[No Abstract] [Full Text] [Related]
9. Cystic fibrosis in the era of CFTR modulators: did the neutrophil slip through the cracks?
Witko-Sarsat V; Burgel PR
J Leukoc Biol; 2024 Feb; 115(3):417-419. PubMed ID: 38193848
[No Abstract] [Full Text] [Related]
10. Unlocking the power of pharmacy services and accelerating access to medications: An update to the impact of pharmacy services on cystic fibrosis transmembrane conductance regulator modulator prescribing at a pediatric cystic fibrosis center.
Wright BA; Knockel LM
Pediatr Pulmonol; 2024 Feb; 59(2):526-527. PubMed ID: 38018663
[No Abstract] [Full Text] [Related]
11. The effectiveness of CFTR modulators in people with CF and rare mutations: A real-world study.
Hanger S; Felton I; Ukor EF; Bowman E; Caldwell C; Banya W; Madge S; Jones AL; Simmonds NJ
Pediatr Pulmonol; 2024 Jan; 59(1):221-224. PubMed ID: 37817743
[No Abstract] [Full Text] [Related]
12. A multidisciplinary model for prenatal care for patients with cystic fibrosis in the era of highly effective modulator therapy.
Li SS; Buschur E; Thung SF; Patel AV; Kirkby S
J Cyst Fibros; 2023 Sep; 22(5):806-810. PubMed ID: 37019745
[No Abstract] [Full Text] [Related]
13. CFTR Modulators for the Gastroenterologist.
Sabharwal S; Lusman SS
J Pediatr Gastroenterol Nutr; 2023 Oct; 77(4):445-447. PubMed ID: 37548477
[No Abstract] [Full Text] [Related]
14. Towards personalized medicine for cystic fibrosis patients with rare mutations.
Csanády L
J Physiol; 2024 Jan; 602(2):257-258. PubMed ID: 38167788
[No Abstract] [Full Text] [Related]
15. Combining biologics and CFTR modulators is safe: A pilot, observational, monocenter study.
Manti S; Giallongo A; Parisi GF; Papale M; Mulè E; Aloisio D; Rotolo N; Leonardi S
Pediatr Pulmonol; 2024 Mar; 59(3):801-804. PubMed ID: 38014605
[No Abstract] [Full Text] [Related]
16. Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay.
Furstova E; Drevinek P; Novotna S; Libik M; Benesova K; Borek-Dohalska L; Sakmarova K; Modrak M; Macek M; Dousova T
Eur Respir J; 2024 Apr; 63(4):. PubMed ID: 38485147
[No Abstract] [Full Text] [Related]
17. How many billions is enough? Prioritizing profits over patients with cystic fibrosis.
McGarry ME; Gibb ER; Laguna TA; O'Sullivan BP; Sawicki GS; Zobell JT
Pediatr Pulmonol; 2023 May; 58(5):1595-1597. PubMed ID: 36722731
[No Abstract] [Full Text] [Related]
18. Cystic fibrosis: What next for the "wonder drug" Kaftrio?
Wise J
BMJ; 2023 Nov; 383():2766. PubMed ID: 37996105
[No Abstract] [Full Text] [Related]
19. Phoenix from the Ashes: Celebrating the 2023 North American Cystic Fibrosis Conference.
Bush A; Ramsey B; Shteinberg M; Martinez F
Am J Respir Crit Care Med; 2023 Nov; 208(9):909-910. PubMed ID: 37756479
[No Abstract] [Full Text] [Related]
20. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
Brewington JJ; McPhail GL; Clancy JP
Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
